BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Su TY, Ye JJ, Yang CC, Huang CT, Chia JH, Lee MH. Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study. Ann Clin Microbiol Antimicrob 2017;16:52. [PMID: 28738848 DOI: 10.1186/s12941-017-0227-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Novais JS, Moreira CS, Silva ACJA, Loureiro RS, Sá Figueiredo AM, Ferreira VF, Castro HC, da Rocha DR. Antibacterial naphthoquinone derivatives targeting resistant strain Gram-negative bacteria in biofilms. Microb Pathog 2018;118:105-14. [PMID: 29550501 DOI: 10.1016/j.micpath.2018.03.024] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
2 Isler B, Harris P, Stewart AG, Paterson DL. An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa. J Antimicrob Chemother 2021;76:550-60. [PMID: 33332545 DOI: 10.1093/jac/dkaa511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
3 Valero A, Isla A, Rodríguez-Gascón A, Canut A, Ángeles Solinís M. Susceptibility of Pseudomonas aeruginosa and antimicrobial activity using PK/PD analysis: an 18-year surveillance study. Enferm Infecc Microbiol Clin (Engl Ed) 2019;37:626-33. [PMID: 31005313 DOI: 10.1016/j.eimc.2019.02.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
4 Grillon A, Chabaud A, Zambardi G, Caniaux I, Jehl F. Breakpoint to MIC quotient: A parameter to rapidly evaluate the in vitro bactericidal activity of β-lactams on Enterobacteriaceae. Int J Antimicrob Agents 2019;53:674-7. [PMID: 30716447 DOI: 10.1016/j.ijantimicag.2019.01.013] [Reference Citation Analysis]
5 Chaijamorn W, Charoensareerat T, Srisawat N, Pattharachayakul S, Boonpeng A. Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study. J Intensive Care 2018;6:61. [PMID: 30221005 DOI: 10.1186/s40560-018-0330-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
6 Gatti M, Viaggi B, Rossolini GM, Pea F, Viale P. An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients. Antibiotics (Basel) 2021;11:33. [PMID: 35052910 DOI: 10.3390/antibiotics11010033] [Reference Citation Analysis]
7 Rodríguez-Núñez O, Periañez-Parraga L, Oliver A, Munita JM, Boté A, Gasch O, Nuvials X, Dinh A, Shaw R, Lomas JM, Torres V, Castón J, Araos R, Abbo LM, Rakita R, Pérez F, Aitken SL, Arias CA, Martín-Pena ML, Colomar A, Núñez MB, Mensa J, Martínez JA, Soriano A. Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam. Open Forum Infect Dis 2019;6:ofz416. [PMID: 31660373 DOI: 10.1093/ofid/ofz416] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
8 Kumar L, Brenner N, Brice J, Klein-Seetharaman J, Sarkar SK. Cephalosporins Interfere With Quorum Sensing and Improve the Ability of Caenorhabditis elegans to Survive Pseudomonas aeruginosa Infection. Front Microbiol 2021;12:598498. [PMID: 33584609 DOI: 10.3389/fmicb.2021.598498] [Reference Citation Analysis]